Loading...
Please wait, while we are loading the content...
Similar Documents
Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review
| Content Provider | MDPI |
|---|---|
| Author | Mata, Danilo Giffoni De Mello Morais Carmona, Carlos Amir Eisen, Andrea Trudeau, Maureen |
| Copyright Year | 2022 |
| Description | Background: Approximately 75% of breast cancer (BC) is associated with luminal differentiation expressing endocrine receptors (ER). For ER+ HER2− tumors, adjuvant endocrine therapy (ET) is the cornerstone treatment. Although relapse events steadily continue, the ET benefits translate to dramatically lengthen life expectancy with bearable side-effects. This review of ER+ HER2− female BC outlines suitable adjuvant treatment strategies to help guide clinical decision making around appropriate therapy. Methods: A literature search was conducted in Embase, Medline, and the Cochrane Libraries, using ER+ HER−, ET BC keywords. Results: In low-risk patients: five years of ET is the standard option. While Tamoxifen remains the preferred selection for premenopausal women, AI is the choice for postmenopausal patients. In the high-risk category: ET plus/minus OFS with two years of Abemaciclib is recommended. Although extended ET for a total of ten years is an alternative, the optimal AI duration is undetermined; nevertheless an additional two to three years beyond the initial five years may be sufficient. In this postmenopausal group, bisphosphonate is endorsed. Conclusions: Classifying the risk category assists in deciding the treatment route and its optimal duration. Tailoring the breadth of ET hinges on a wide array of factors to be appraised for each individualized case, including weighing its benefits and harms. |
| Ending Page | 4969 |
| Page Count | 14 |
| Starting Page | 4956 |
| e-ISSN | 17187729 |
| DOI | 10.3390/curroncol29070394 |
| Journal | Current Oncology |
| Issue Number | 7 |
| Volume Number | 29 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2022-07-13 |
| Access Restriction | Open |
| Subject Keyword | Current Oncology Womens Studies Early Breast Cancer Premenopausal Postmenopausal Hormone Receptor Positive Her2-negative Endocrine Therapy Selective Estrogen Receptor Aromatase Inhibitors Adjuvant Cyclin-dependent Kinases 4/6 Inhibitors Bisphosphonates |
| Content Type | Text |
| Resource Type | Article |
